In the 100kGP, which, if not unbiased, had very few exclusion criteria for recruitment, we found pathogenic IDH1 or IDH2 mutations in 0.58% of CRC patients, a little lower than the frequencies reported previously [8, 9]. Here, IDH2 is linked to colorectal carcinoma.